目的：检测人脑恶性胶质瘤组织中IL13Rα2和增殖细胞核抗原（proliferating cell nuclear antigen, PCNA）的表达强度，分析其与患者临床病理特点和预后之间的关系。方法：选取20022006年温州医学院附属第一医院手术治疗的43例恶性胶质瘤标本；采用免疫组织化学法检测并用图像分析系统分析IL13Rα2和PCNA在恶性胶质瘤组织中的表达，分析两者间的相关性；分析它们与临床特征和预后的关系。结果：(1) 43例恶性胶质瘤标本有40例(93%)IL13Rα2阳性表达和36例(84%)PCNA阳性表达；(2) IL13Rα2和PCNA表达强度与肿瘤部位和肿瘤大小无相关性(P>0.05)；在WHOⅢ级与Ⅳ级间两者表达强度差异均有统计学意义（P=0.031, P=0.002）；在生存时间≤6个月与>6个月患者间IL13Rα2 表达强度差异有统计学意义(P=0.028)。(3)IL13Rα2和PCNA的表达强度呈显著的正相关(r=0.653,P=0.000)。结论：人恶性胶质瘤组织中IL13Rα2和PCNA均高表达，前者表达强度与肿瘤恶性分级和患者预后密切相关，在恶性胶质瘤的诊断和预后判断中具有潜在的临床应用价值。

Objective:To examine the expression of IL13Rα2 and proliferating cell nuclear antigen (PCNA) in malignant glioma, and to investigate its relationship with clinical pathological characteristics and prognosis. Methods:Fortythree surgical samples of malignant glioma were obtained from First Affiliated Hospital of Wenzhou Medical College during 20022006. Expression of IL13Rα2 and PCNA proteins was examined by immunohistochemistry staining, and the integrated optical density (IOD) was analyzed by image analysis system. The correlation between the expression of IL13Rα2 with that of PCNA, and their relationship with clinical characteristics and prognosis of glioma were studied.Results: (1) The positive rates of IL13Rα2 and PCNA in malignant glioma tissues were 93% (40/43) and 84% (36/43), respectively. (2) No relationship of IL13Rα2 and PCNA expression with the location and tumor size of glioma was found (P>0.05). The expression of IL13Rα2 and PCNA in glioma was significantly different between Ⅲ grade and Ⅳ grade glioma tissues (P=0.031, P=0.002). Patients who survived less than 6 months had a significantly higher expression of IL13Rα2 than those who survived more than 6 months (P=0.028). (3) The expression of IL13Rα2 was positively correlated with that of PCNA (r=0.653, P=0.000). Conclusion: IL13Rα2 and PCNA are overexpressed in malignant glioma tissues, and IL13Rα2 expression is correlated with differentiation grade and prognosis of glioma. IL13Rα2 has potential roles in clinical diagnosis and prognositic evaluation of malignant glioma.